Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 5/20 | 0.35 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP14 | P50281 | 2/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456952 | 1.00 | POLB (0.37) | POLBARALDH1A1KMT2AMGLL | |
| SCHEMBL6024319 | 1.00 | POLB (0.37) | POLBARALDH1A1KMT2AMGLL | |
| SCHEMBL2173554 | 0.93 | POLB (0.38) | POLBARMGLLADAM10MMP2 | |
| SCHEMBL2173557 | 0.85 | AR (0.37) | POLBARALDH1A1KMT2AMGLL | |
| SCHEMBL3456406 | 0.83 | CTSK (0.42) | POLBARALDH1A1KMT2AADAM10 | |
| SCHEMBL6024520 | 0.83 | CTSK (0.40) | ARADAM10MMP2MMP9MMP14 | |
| SCHEMBL3456876 | 0.83 | CTSK (0.40) | ARADAM10MMP2MMP9MMP14 | |
| SCHEMBL3456872 | 0.83 | CTSK (0.40) | ARADAM10MMP2MMP9MMP14 | |
| SCHEMBL2176445 | 0.83 | CTSS (0.41) | POLBARALDH1A1KMT2AADAM10 | |
| SCHEMBL2176442 | 0.80 | CTSK (0.42) | POLBARALDH1A1KMT2AADAM10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2015-01-22 | — | — | US | disclosed |
| US-8853243-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2264030-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | Incyte Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025056-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP2, MMP14 | POLB 1479/4885AR 2463/4885ALDH1A1 497/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | POLB 2157/4885AR 2166/4885ALDH1A1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.